ArticleAlzheimer's research & therapy2018
The EMIF-AD PreclinAD study: study design and baseline cohort overview.
Article in Alzheimer's research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 85 citations in OpenAlex.
- Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2020Trial
- CSF Proteomic Profiles Associated With White Matter Integrity in Cognitively Normal Older Adults With and Without Amyloid Pathology.Neurology · 2026Article
- Association of tear fluid glutathione synthetase and glutathione levels with amyloid positivity.Scientific reports · 2026Article
- Cerebrospinal fluid proteomic signatures revealResearch square · 2026Article
- CSF proteomic quantitative trait loci mapping reveals genetic insights into Alzheimer's disease.Molecular neurodegeneration advances · 2026Article
- Integrative analysis of cerebrospinal fluid biomarkers, metabolomics, and polygenic risk reveals novel metabolite associations with Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2025Article
- The association of diabetes with Alzheimer's disease biomarkers and vascular burden across European aging and memory clinic cohorts.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Epigenetic age acceleration in peripheral blood correlates with brain-MRI age acceleration.Brain : a journal of neurology · 2025Article
- Quantitative trait loci mapping of circulating metabolites in cerebrospinal fluid to uncover biological mechanisms involved in brain-related phenotypes.Molecular psychiatry · 2025Article
- Subcortical gray matter volumes and 5-year dementia risk in individuals with subjective cognitive decline or mild cognitive impairment: A multi-cohort analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Cerebrospinal Fluid Amyloid and Tau Biomarker Changes Across the Alzheimer Disease Clinical Spectrum.JAMA network open · 2025Article
- Amyloid-β deposition predicts oscillatory slowing of magnetoencephalography signals and a reduction of functional connectivity over time in cognitively unimpaired adults.Brain communications · 2025Article
- CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals.Molecular neurodegeneration · 2024Article
- Longitudinal Assessment of Retinal Microvasculature in Preclinical Alzheimer's Disease.Investigative ophthalmology & visual science · 2024Article
- Predicting Cognitive Decline in Amyloid-Positive Patients With Mild Cognitive Impairment or Mild Dementia.Neurology · 2024Article
- Post-GWAS multiomic functional investigation of the TNIP1 locus in Alzheimer's disease highlights a potential role for GPX3.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Contributions of amyloid beta and cerebral small vessel disease in clinical decline.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Is the association between blood pressure and cognition in the oldest-old modified by physical, vascular or brain pathology markers? The EMIF-AD 90 + Study.BMC geriatrics · 2023Article
- Performance of a [Neurology · 2023Article
- Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study.Alzheimer's research & therapy · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundAmyloid pathology is the pathological hallmark in Alzheimer's disease (AD) and can precede clinical dementia by decades. So far it remains unclear how amyloid pathology leads to cognitive impairment and dementia. To design AD prevention trials it is key to include cognitively normal subjects at high risk for amyloid pathology and to find predictors of cognitive decline in these subjects. These goals can be accomplished by targeting twins, with additional benefits to identify genetic and environmental pathways for amyloid pathology, other AD biomarkers, and cognitive decline.
methodsFrom December 2014 to October 2017 we enrolled cognitively normal participants aged 60 years and older from the ongoing Manchester and Newcastle Age and Cognitive Performance Research Cohort and the Netherlands Twins Register. In Manchester we included single individuals, and in Amsterdam monozygotic twin pairs. At baseline, participants completed neuropsychological tests and questionnaires, and underwent physical examination, blood sampling, ultrasound of the carotid arteries, structural and resting state functional brain magnetic resonance imaging, and dynamic amyloid positron emission tomography (PET) scanning with [
resultsWe included 285 participants, who were on average 74.8 ± 9.7 years old, 64% female. Fifty-eight participants (22%) had an abnormal amyloid PET scan.
conclusionsA rich baseline dataset of cognitively normal elderly individuals has been established to estimate risk factors and biomarkers for amyloid pathology and future cognitive decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.